-
Je něco špatně v tomto záznamu ?
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
AD. Zelenetz, JC. Barrientos, JR. Brown, B. Coiffier, J. Delgado, M. Egyed, P. Ghia, Á. Illés, W. Jurczak, P. Marlton, M. Montillo, F. Morschhauser, AS. Pristupa, T. Robak, JP. Sharman, D. Simpson, L. Smolej, E. Tausch, AH. Adewoye, LK. Dreiling,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- bendamustin hydrochlorid aplikace a dávkování MeSH
- chemorezistence účinky léků MeSH
- chinazolinony aplikace a dávkování MeSH
- chronická lymfatická leukemie farmakoterapie patologie MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- lidé středního věku MeSH
- lidé MeSH
- lokální recidiva nádoru farmakoterapie patologie MeSH
- míra přežití MeSH
- následné studie MeSH
- prognóza MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- puriny aplikace a dávkování MeSH
- rituximab aplikace a dávkování MeSH
- senioři MeSH
- staging nádorů MeSH
- záchranná terapie * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. METHODS: For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m(2) intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6) in addition to either twice-daily oral idelalisib (150 mg) or placebo until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by high-risk features (IGHV, del[17p], or TP53 mutation) and refractory versus relapsed disease. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01569295. FINDINGS: Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7-18), median progression-free survival was 20·8 months (95% CI 16·6-26·4) in the idelalisib group and 11·1 months (8·9-11·1) in the placebo group (hazard ratio [HR] 0·33, 95% CI 0·25-0·44; p<0·0001). The most frequent grade 3 or worse adverse events in the idelalisib group were neutropenia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia (99 [47%] of 209) and thrombocytopenia (27 [13%]). An increased risk of infection was reported in the idelalisib group compared with the placebo group (grade ≥3 infections and infestations: 80 [39%] of 207 vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections in the idelalisib group and three from infections in the placebo group. INTERPRETATION: Idelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia. However, careful attention needs to be paid to management of serious adverse events and infections associated with this regimen during treatment selection. FUNDING: Gilead Sciences Inc.
CHRU Lille Unité GRITA Department of Haematology Université de Lille Lille France
Department of Haematology Centre Hospitalier Lyon Sud Pierre Bénite France
Department of Haematology Hospital Clínic Barcelona Spain
Department of Haematology Jagiellonian University Krakow Poland
Department of Haematology Medical University of Lodz and Copernicus Memorial Hospital Lodz Poland
Department of Haematology Niguarda Cancer Center Niguarda Hospital Milan Italy
Department of Haematology Oncology St James's University Hospital Leeds UK
Department of Haematology Ryazan Regional Clinical Hospital Ryazan Russia
Department of Haematology Somogy County Kaposi Mór Hospital Kaposvar Hungary
Department of Haematology University of Debrecen Debrecen Hungary
Department of Internal Medicine 3 Ulm University Ulm Germany
Department of Medical Oncology Dana Farber Cancer Institute Harvard Medical School Boston MA USA
Gilead Sciences Foster City CA USA
Hofstra Northwell School of Medicine Hofstra University New Hyde Park NY USA
North Shore Hospital Takapuna Auckland New Zealand
US Oncology Research Willamette Valley Cancer Institute and Research Center Eugene OR USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17023324
- 003
- CZ-PrNML
- 005
- 20240313101412.0
- 007
- ta
- 008
- 170720s2017 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(16)30671-4 $2 doi
- 035 __
- $a (PubMed)28139405
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Zelenetz, Andrew D $u Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA. Electronic address: zeleneta@mskcc.org.
- 245 10
- $a Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial / $c AD. Zelenetz, JC. Barrientos, JR. Brown, B. Coiffier, J. Delgado, M. Egyed, P. Ghia, Á. Illés, W. Jurczak, P. Marlton, M. Montillo, F. Morschhauser, AS. Pristupa, T. Robak, JP. Sharman, D. Simpson, L. Smolej, E. Tausch, AH. Adewoye, LK. Dreiling, Y. Kim, S. Stilgenbauer, P. Hillmen,
- 520 9_
- $a BACKGROUND: Bendamustine plus rituximab is a standard of care for the management of patients with relapsed or refractory chronic lymphocytic leukaemia. New therapies are needed to improve clinically relevant outcomes in these patients. We assessed the efficacy and safety of adding idelalisib, a first-in-class targeted phosphoinositide-3-kinase δ inhibitor, to bendamustine plus rituximab in this population. METHODS: For this international, multicentre, double-blind, placebo-controlled trial, adult patients (≥18 years) with relapsed or refractory chronic lymphocytic leukaemia requiring treatment who had measurable lymphadenopathy by CT or MRI and disease progression within 36 months since their last previous therapy were enrolled. Patients were randomly assigned (1:1) by a central interactive web response system to receive bendamustine plus rituximab for a maximum of six cycles (bendamustine: 70 mg/m(2) intravenously on days 1 and 2 for six 28-day cycles; rituximab: 375 mg/m(2) on day 1 of cycle 1, and 500 mg/m(2) on day 1 of cycles 2-6) in addition to either twice-daily oral idelalisib (150 mg) or placebo until disease progression or intolerable study drug-related toxicity. Randomisation was stratified by high-risk features (IGHV, del[17p], or TP53 mutation) and refractory versus relapsed disease. The primary endpoint was progression-free survival assessed by an independent review committee in the intention-to-treat population. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01569295. FINDINGS: Between June 26, 2012, and Aug 21, 2014, 416 patients were enrolled and randomly assigned to the idelalisib (n=207) and placebo (n=209) groups. At a median follow-up of 14 months (IQR 7-18), median progression-free survival was 20·8 months (95% CI 16·6-26·4) in the idelalisib group and 11·1 months (8·9-11·1) in the placebo group (hazard ratio [HR] 0·33, 95% CI 0·25-0·44; p<0·0001). The most frequent grade 3 or worse adverse events in the idelalisib group were neutropenia (124 [60%] of 207 patients) and febrile neutropenia (48 [23%]), whereas in the placebo group they were neutropenia (99 [47%] of 209) and thrombocytopenia (27 [13%]). An increased risk of infection was reported in the idelalisib group compared with the placebo group (grade ≥3 infections and infestations: 80 [39%] of 207 vs 52 [25%] of 209). Serious adverse events, including febrile neutropenia, pneumonia, and pyrexia, were more common in the idelalisib group (140 [68%] of 207 patients) than in the placebo group (92 [44%] of 209). Treatment-emergent adverse events leading to death occurred in 23 (11%) patients in the idelalisib group and 15 (7%) in the placebo group, including six deaths from infections in the idelalisib group and three from infections in the placebo group. INTERPRETATION: Idelalisib in combination with bendamustine plus rituximab improved progression-free survival compared with bendamustine plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukaemia. However, careful attention needs to be paid to management of serious adverse events and infections associated with this regimen during treatment selection. FUNDING: Gilead Sciences Inc.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a bendamustin hydrochlorid $x aplikace a dávkování $7 D000069461
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a chemorezistence $x účinky léků $7 D019008
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická lymfatická leukemie $x farmakoterapie $x patologie $7 D015451
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lokální recidiva nádoru $x farmakoterapie $x patologie $7 D009364
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a puriny $x aplikace a dávkování $7 D011687
- 650 _2
- $a chinazolinony $x aplikace a dávkování $7 D052999
- 650 _2
- $a rituximab $x aplikace a dávkování $7 D000069283
- 650 12
- $a záchranná terapie $7 D016879
- 650 _2
- $a míra přežití $7 D015996
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Barrientos, Jacqueline C $u Hofstra Northwell School of Medicine, Hofstra University, New Hyde Park, NY, USA.
- 700 1_
- $a Brown, Jennifer R $u Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
- 700 1_
- $a Coiffier, Bertrand, $d 1947-2019 $u Department of Haematology, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. $7 xx0314848
- 700 1_
- $a Delgado, Julio $u Department of Haematology, Hospital Clínic, Barcelona, Spain.
- 700 1_
- $a Egyed, Miklós $u Department of Haematology, Somogy County Kaposi Mór Hospital, Kaposvar, Hungary.
- 700 1_
- $a Ghia, Paolo $u Division of Experimental Oncology and Department of Onco-Haematology, IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy.
- 700 1_
- $a Illés, Árpád $u Department of Haematology, University of Debrecen, Debrecen, Hungary.
- 700 1_
- $a Jurczak, Wojciech $u Department of Haematology, Jagiellonian University, Krakow, Poland.
- 700 1_
- $a Marlton, Paula $u Department of Haematology, Princess Alexandra Hospital, University of Queensland, School of Medicine, Brisbane, Australia.
- 700 1_
- $a Montillo, Marco $u Department of Haematology, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy.
- 700 1_
- $a Morschhauser, Franck $u CHRU Lille, Unité GRITA, Department of Haematology, Université de Lille, Lille, France.
- 700 1_
- $a Pristupa, Alexander S $u Department of Haematology, Ryazan Regional Clinical Hospital, Ryazan, Russia.
- 700 1_
- $a Robak, Tadeusz $u Department of Haematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland.
- 700 1_
- $a Sharman, Jeff P $u US Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.
- 700 1_
- $a Simpson, David $u North Shore Hospital, Takapuna, Auckland, New Zealand.
- 700 1_
- $a Smolej, Lukáš $u 4th Department of Internal Medicine-Haematology, University Hospital and Charles University in Prague, Faculty of Medicine in Hradec Králové, Hradec Králové, Czech Republic.
- 700 1_
- $a Tausch, Eugen $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Adewoye, Adeboye H $u Gilead Sciences, Foster City, CA, USA. $7 gn_A_00001754
- 700 1_
- $a Dreiling, Lyndah K $u Gilead Sciences, Foster City, CA, USA.
- 700 1_
- $a Kim, Yeonhee $u Gilead Sciences, Foster City, CA, USA.
- 700 1_
- $a Stilgenbauer, Stephan $u Department of Internal Medicine III, Ulm University, Ulm, Germany.
- 700 1_
- $a Hillmen, Peter $u Department of Haematology/Oncology, St James's University Hospital, Leeds, UK.
- 773 0_
- $w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 18, č. 3 (2017), s. 297-311
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28139405 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20170720 $b ABA008
- 991 __
- $a 20240313101407 $b ABA008
- 999 __
- $a ok $b bmc $g 1239005 $s 984237
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 18 $c 3 $d 297-311 $e 20170128 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20170720
